Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance

Families appealing the dismissal of over 500 lawsuits against Kenvue (KVUE.N), alleging Tylenol caused autism, are urging the 2nd U.S. Circuit Court of Appeals to consider President Trump's recent public advice for pregnant women to avoid acetaminophen, citing research from one of their experts. This development introduces a political dimension to the litigation, previously dismissed due to a lack of sound scientific methodology, and could impact Kenvue's legal exposure despite the company's assertion that the FDA has not established a causal link.

Analysis

Kenvue Inc. (KVUE.N) is confronting a renewed legal challenge as plaintiffs in the Tylenol litigation appeal the dismissal of over 500 lawsuits. The appeal introduces a novel argument by urging the 2nd U.S. Circuit Court of Appeals to consider recent public health advice from President Trump against acetaminophen use during pregnancy. This political development is being leveraged by plaintiffs because the administration's stance was reportedly influenced by one of the same scientific experts whose methodology was previously disqualified by U.S. District Judge Denise Cote as an "unstructured approach" allowing for "cherry-picking." Despite this headline risk, Kenvue's defense appears well-supported by the initial court ruling, the FDA's position that a causal relationship has not been established, and a recent large-scale 2024 Swedish study of 2.5 million children that found no causal link. Legal experts cited in the report remain skeptical that the President's non-scientific commentary will significantly sway the appellate court's decision, with arguments slated for October 6.

Key Decisions for Investors

• Investors should monitor the October 6th appeal hearing, as an unexpected reversal of the lawsuits' dismissal would materially increase Kenvue's litigation risk and potential liabilities.
• Despite the negative headline risk from the plaintiffs' political maneuvering, the fundamental legal and scientific case appears to favor Kenvue, supported by the prior court dismissal and the FDA's official position.
• Consider that the current legal battle, while creating short-term volatility, may not alter the long-term outlook, as legal experts believe the executive branch's comments are unlikely to influence the court's scientifically-grounded legal analysis.